


**World Dementia
Council** Leading the Global Action
Against Dementia

Global dialogue on prevention: Agenda and participants

The dementia landscape
project

9 February 2021





Welcome

We are excited that you can join us at this virtual World Dementia Council prevention workshop. The world's first G8 dementia summit was held in 2013 in London, where the international community of top researchers, funders, pharmaceutical companies and governments committed to accelerate research, improve care, raise awareness of dementia and reduce the risk of someone getting dementia.


Everyone who works in this field would agree the best treatment for dementia would be not getting it in the first place. Since 2013 our understanding of the underlying risk of developing dementia has increased significantly. There is evidence that the prevalence of dementia is lower than expected in some countries because of higher levels of education and healthier lifestyles, suggesting a prevention could be possible. According to the World Health Organization, around 50 million people have dementia worldwide and this number is projected to reach 152 million in 2050. In 2015, the global societal cost of dementia was estimated to be \$818 billion, and this is projected to rise up to \$2 trillion by 2030. The potential of developing population and individual prevention programmes that might lower the future health, social and economic burden of dementia provides strong motivation to examine how we can work together at a societal and policy level to bring about these changes.

But prevention interventions at the level of populations and individuals are challenging. In an attempt to find ideas to outreach, convince and accelerate a prevention momentum, we have invited three speakers to share their reflections on the prevention agenda: firstly on the potential, challenge and impact of public health programmes generally, secondly on prevention in the dementia field and finally on a country's experience of prevention programmes.

At the conclusion of the overview presentations there will be an open discussion. The session will last for 90 minutes. We look forward to having you participate in this exciting workshop.




Professor Kaarin Anstey
Professor of psychology
and director, University of
New South Wales Ageing
Futures Institute



Professor Philippe Amouyel
General director, Fondation Plan
Alzheimer (France) and professor
of epidemiology and public health,
University Hospital of Lille



Logistics and agenda



Tuesday 9 February 2021


Virtual meeting

07:00 - 08:30 GMT London
08:00 - 09:30 CET Central Europe
12:30 - 14:00 IST New Delhi
16:00 - 17:30 JST Tokyo
18:00 - 19:30 AEDT Sydney



Section	Speaker(s)
Welcome	Lenny Shallcross
Opening remarks	Kaarin Anstey
Opening presentations	Chaired by Kaarin Anstey
Lessons from other public health risk reduction initiatives	Michele Cecchini
Dementia prevalence and public health trends	Carol Brayne
Dementia prevention programmes and their practical implementation	Yoshiki Niimi
Group conversation	Introduced and moderated by Philippe Amouyel
Closing perspectives	Kaarin Anstey Philippe Amouyel
Closing thanks	Lenny Shallcross

Co-chairs



Professor Kaarin Anstey

Kaarin Anstey is a professor of psychology and conducts public health research into dementia risk reduction ranging from analysis of cohort studies, development of risk assessment tools, and conducting risk reduction trials. Kaarin is the director of the University of New South Wales Ageing Futures Institute and is a conjoint senior principal research scientist at Neuroscience Research Australia. She chairs the International Research Network on Dementia Prevention and is a member of the governance committee of the Global Council on Brain Health, an initiative supported by AARP.




Professor Philippe Amouyel

Philippe Amouyel is general director of Fondation Alzheimer (France), professor of epidemiology and public health at the University Hospital of Lille, and a member of the World Dementia Council. Since 1998, he has headed a research unit of 110 people dedicated to public health and the molecular epidemiology of age-related diseases. He has published more than 850 scientific articles and participated in the discovery of 90% of the confirmed genetic loci predisposing to sporadic Alzheimer's disease. At the European level, Philippe also chairs the European Joint Programming Initiative on Research on Neurodegenerative Diseases (JPND) and Alzheimer's in particular. The main objective of JPND is to combine the strength of European and global research to tackle these diseases more efficiently.



Speakers



Professor Carol Brayne


Carol Brayne CBE is a Professor of Public Health Medicine and Co-Chair of the Cambridge Public Health Interdisciplinary Centre at the University of Cambridge. She is a medically qualified epidemiologist and public health academic. Her main research has been longitudinal studies of older people following changes over time with a public health perspective and focus on the brain. She is lead principal investigator in the MRC CFA Studies and other population based studies and has played a lead role in teaching and training in epidemiology and public health at Cambridge University. She is a Fellow of the Academy of Medical Sciences and an NIHR Senior Investigator Emeritus.



Dr Michele Cecchini

Michele Cecchini is responsible for the programme on Public Health at the OECD – the Organisation for Economic Co-operation and Development. Michele’s research interests include priority setting and programme evaluation of policies influencing population health. He is the editor, author and co-author of a large number of publications on the economic aspects of public health, including the recent OECD flagship publications on antimicrobial resistance, overweight and alcohol. Michele represents OECD in the board of the Global AMR R&D Hub and holds a position of adjunct professor in applied health economics at the School of Public Health of the University of Siena (Italy). Previously, he held a visiting position at the Duke-NUS Graduate Medical School in Singapore and served as a temporary advisor to a number of government and international agencies, including WHO, IARC, EC and the World Bank. After obtaining a degree in Medicine and Surgery from the University of Genoa, Michele completed his specialist training in Public Health at the University of Siena. He also obtained a master’s degree in Health Policy, Planning and Financing from the London School of Economics and the London School of Hygiene and Tropical Medicine and a PhD from Imperial College London.





Dr Yoshiki Niimi

Dr Yoshiki Niimi is a special appointed lecturer at the Unit for early and exploratory clinical development, University of Tokyo. Dr Niimi participates in the Japanese TRC-PAD (J-TRC) and the DIAN-Japan as a site PI at Tokyo university. He had worked at the Ministry of Health, Labour, and Welfare Japan as a senior specialist for dementia from 2012 till 2015. During that period, the G8 Dementia Summit and serial legacy events were held. He played a pivotal role in promoting the Global Dementia Legacy Event Japan and formulating the Japanese national dementia plan or 'New orange plan'. By utilizing this experience, he serves as the Vice-chair of the Social problem committee of the Japan Society for dementia research.




Lenny Shallcross

Lenny Shallcross is executive director at the World Dementia Council. Prior to that he was Head of Community Engagement leading programmes across the UK to establish Dementia Friendly Communities. This includes the Dementia Friends programme which is the biggest health social movement campaign delivered by 10,000 volunteers that have recruited 2 million individuals through a community, digital and corporate offer. Before working for Alzheimer's Society he worked in the UK government as a political adviser at DCMS and the DoH, as well as working in Parliament and for the Labour Party.



Discussion participants



Professor Emiliano Albanese

Professor of Public Health and director, USI Institute of Public Health, Geneva


I am an epidemiologist and a clinician. I trained at the LSHTM and worked at the NIH, as a post-doctoral researcher in neuro-epidemiology. I have worked in the field of public and global mental health for many years, in close collaboration with the WHO Department of Mental Health and Substance Abuse, and I am director of a WHO collaborating center in mental health training and research since 2015 (in Geneva). I am based in Switzerland where I am full professor of public health, director of the USI Institute of Public Health, and associated professor of public mental health in the Department of Psychiatry of the Faculty of Medicine in Geneva. This allows me integrate population and epidemiological approaches with a clinical and medical expertise in mental health. My main research focus is dementia, its determinants and impact, and the implementation of a coordinated, global public health response to it.



Dr Charles Alessi

Chief Clinical Officer, Healthcare Information and Management Systems Society (HIMSS)

Dr Charles Alessi is a globally recognized and trusted leader in health care. He brings to HIMSS a wealth of experience, particularly around health systems and the interface between healthcare, social care and the personalization of wellness. He is a physician in London, with more than 35 years of experience in all aspects of clinical practice in the UK National Health Service. Most recently, he served as the Chairman of the National Association of Primary Care, part of the NHS confederation, where he was at the heart of the recent health and social care reforms. He is also the Senior Advisor to Public Health England, a position leading thought leadership around productive healthy ageing including dementia, targeting risk reduction. Furthermore, he fulfils key roles in PHE around digital interventions, particularly those that involve behavioral change.



**Professor
Sandrine Andrieu**

Professor of public health, chair of the clinical epidemiology and public health department at the Toulouse University Hospital

Sandrine Andrieu (M.D, PhD) is professor of public health, chair of the clinical epidemiology and public health department at the Toulouse University Hospital and adjunct professor at the University New Mexico (USA).


Since 2009, she's responsible of aging research team in the center for Epidemiology and research in population health. She served as director of the research center for Epidemiology and research in population health (UMR1027 INSERM University Paul Sabatier) from 2011 to 2020. She has published more than 250 international papers and book chapters in the field of aging. She is involved in large prevention studies in the field of neuro-degenerative disease (GuidAge, MAPT) and in European projects (HATICE study, MIND-AD, PRODEMOS study). Her main topic of research is Alzheimer's disease and prevention of age-related loss of functions, and healthy aging. She's past-president of the French National Society of Geriatrics and Gerontology.



Dr Alex Bahar-Fuchs

Senior Research Fellow, University of Melbourne

Alex is a researcher and clinical neuropsychologist specializing in the field of cognitive ageing, and the co-leader of the CITE research group in the Department of Psychiatry, the University of Melbourne. His earlier research focused on early detection of cognitive decline and dementia, and over the past decade mainly on the development and evaluation of non-pharmacological interventions aimed at primary and secondary prevention of cognitive decline and dementia. Alex's research contributions have been recognised in the form of several awards, including a Churchill Fellowship, Alzheimer's Australia Fellowship, and two consecutive Fellowships from the National Health and Medical Research Council. In January 2017, Alex Joined the Academic Unit for Psychiatry of Old Age at the University of Melbourne and he continues working as a clinician in private practice.



Matthew Baumgart

Vice president of Health Policy, Alzheimer's Association


Matthew Baumgart is vice president of Health Policy for the Alzheimer's Association, leading a range of projects at the intersection of policy and programs to achieve an aggressive agenda that serves all those affected by the disease. In this role, he heads the BOLD Public Health Center of Excellence on Dementia Risk Reduction, funded by the CDC. In addition, Baumgart directs the Association's global public policy efforts, working in collaboration with Alzheimer Disease International, the World Dementia Council and the World Health Organization. Baumgart joined the Association in 2009 and has served in roles overseeing policy development, public health policy initiatives, federal affairs and state government affairs. Prior to joining the Association, Baumgart spent nearly 20 years working in the U.S. Senate in a variety of roles, including legislative director for Sen. Barbara Boxer (D-Calif.) and legislative assistant for over a decade to Sen. Joe Biden (D-Del.).



Dr Claudine Berr

Senior researcher, INSERM, University of Montpellier

Dr Claudine Berr (Institute of Neurosciences of Montpellier, Inserm U1298, France) is an epidemiologist. Her major research interests are in identification of modifiable risk factors of Alzheimer's disease and age-related cognitive disorders, both at the individual and contextual levels. She has extensive experience in the design, management, and scientific output of large population-based cohort studies in France and numerous responsibilities in the evaluation of research and public health policies in France. As president of the "Chronic Diseases Commission" of the French High Council of Public Health, she coordinated a report on the prevention of Alzheimer's disease which synthesizes knowledge and proposes recommendations that can be applied to everyday life.



Dr Marco Blom

Scientific director,
Alzheimer Nederland


Marco Blom (1961) is scientific director of Alzheimer Nederland (Alzheimer's Society in the Netherlands). He is psychogerontologist and since 1987 involved in organisations and projects on dementia. He started his career at a Community Mental Health Centre in The Hague and was in 1991 appointed at the National Institute of Care and Welfare (now called Vilans) in Utrecht. In March 1997 he joined Alzheimer Nederland. He was involved in the development of the Alzheimer Cafes, the academic Alzheimer Research Centres and the online platform (www.dementie.nl) for people with dementia and their family caregivers. Other affiliations: board member of the Delta Plan Dementia, the national program on dementia in the Netherlands (2013 – 2020), member of the editorial board of the Netherlands Journal of Psychogeriatrics (called Denkbeeld) and board member of Alzheimer Europe (since 2018).



Dr Tobias Bittner

Biomarker Leader
for the Alzheimer's
disease (AD) Franchise,
F.Hoffmann-LaRoche

Dr. Bittner is a trained neuroscientist, with a history of more than 15 years in developing therapeutics, diagnostics, and biomarkers in neuroscience in pharma and diagnostic industry and academia. Currently, Dr. Bittner serves as the Biomarker Leader for the Alzheimer's disease (AD) Franchise at F.Hoffmann-LaRoche and Genentech with the goal to evaluate and apply state-of-the-art fluid, imaging, genetic, and digital biomarkers to molecules in pre-clinical and clinical development and to transform the diagnostic pathway in Alzheimer's disease.



Dr Christopher Chen

Associate Professor,
National University of
Singapore

Dr Christopher Chen is a Senior Clinician-Scientist at the Departments of Pharmacology and Psychological Medicine, Yong Loo Lin School of Medicine, National University of Singapore, and Director of the Memory Aging and Cognition Centre. His early medical and research training was at Cambridge, Oxford and the Institute of Neurology, London. Since returning to Singapore, Dr Chen has developed multi-disciplinary research programmes with extensive international collaborations. His major research and clinical interests are in neuroimaging, molecular biology and treatment of stroke and dementia.



Dr Gaël Chételat

Director of Research,
Inserm


Gaël Chételat is Director of Research at Inserm. She is responsible of a research team named «Multimodal Neuroimaging and Lifestyle in Ageing and Dementia». Her work is devoted to the understanding of the mechanisms underlying ageing and dementia processes and the lifestyle factors that could prevent or delay age-associated disorders. She is mainly involved in clinical studies using multimodal neuroimaging techniques including MRI and PET. Her research team is also interested in promoting healthy ageing and wellbeing through non-pharmaceutical interventions. In particular, Gaël Chételat is coordinating an H2020 European grant (www.silversantestudy.eu, PHC22, 2015-2020) investigating the impact of English learning and meditation training on mental health and well-being in ageing populations.



Neerja Chowdhary

Technical Officer,
Department of Mental
Health and Substance
Use, World Health
Organization

Technical Officer in the Department of Mental Health and Substance Use, World Health Organization, Geneva. A psychiatrist by training, she works as part of WHO's brain health team, supporting implementation of the global action plan on the public health response to dementia 2017-2025. She coordinated the development of the WHO guidelines on risk reduction of cognitive decline and dementia



Dr Kay Deckers

Assistant Professor,
School for Mental
Health and
Neuroscience and
the Alzheimer Center
Limburg, Maastricht
University


Kay Deckers is an Assistant Professor at the School for Mental Health and Neuroscience and the Alzheimer Center Limburg at Maastricht University (The Netherlands). He was trained in neuropsychology and epidemiology. In his research, he investigates the effects of risk and protective factors for cognitive decline and dementia. He was one of the developers of the well-validated “Lifestyle for BRAin health” (LIBRA) score, a modifiable dementia risk index which quantifies someone’s potential for dementia risk reduction. Additionally, he is very concerned with preventive strategies for a brain-healthy society (e.g. public health awareness campaigns, development of a brain-health tool (MijnBreincoach app), implementation of dementia risk reduction in general practices). Kay is also member of the management team of the FINGER-NL trial, a 2-year multi-domain lifestyle intervention program to promote brain health in older adults.



Dr Amit Dias

Assistant professor,
department of
Preventative and
Social Medicine, Goa
Medical College

Amit Dias, MD, DTM&H, DGM, DCT, is an epidemiologist and geriatrician who is currently the assistant professor in the department of Preventative and Social Medicine at Goa Medical College in Goa. Dr. Dias received his MBBS and MD from Goa Medical College at Goa University. He received his DTM&H and DCT from the London School of Tropical Medicine and Hygiene in the UK. He has his PGDGM from the M.S. Ramyah Medical College at Indira Gandhi Open University in New Delhi. Additionally, he is the chairperson of Sangath, an NGO for bridging the treatment gap for mental health. Dr. Dias is the founder secretary of the Dementia Society of Goa and the coordinator of the 10/66 Dementia Research Group in India. He is the coordinator of the Medical and Scientific Advisory Panel and former Jt. secretary for the Alzheimer’s and Related Disorders Society of India (ARDSI). He was one of the authors of the National Dementia India report 2010 that was presented to the Government of India.



Franca Gatto

Director of the Aging, Seniors and Dementia Division, Centre for Health Promotion at the Public Health Agency of Canada


Franca Gatto is the Director of the Aging, Seniors and Dementia Division in the Centre for Health Promotion at the Public Health Agency of Canada, a position she has held since September 2017. Franca works with stakeholder organizations and provincial and territorial governments across Canada, and is the federal government focal point for health issues affecting Canada's older adult population. Through federal investments, partnerships and policy leadership, the Division of Aging, Seniors and Dementia seeks to promote healthy aging in the areas of dementia, injury prevention, and mental health. Franca and her team is responsible for the development of Canada's first national dementia strategy, A Dementia Strategy for Canada: Together We Aspire, launched in 2019. Along with her team she is spearheading the implementation of the national dementia strategy and is administering federal investments of \$70M over five years to support key components of the strategy.



Jacqueline Hoogendam

Dementia policy co-ordinator on Long-Term Care, Ministry of Health, Welfare and Sport, The Netherlands

Dementia policy co-ordinator/co-ordinator international affairs on Long-Term Care, Ministry of Health, Welfare and Sport, The Netherlands. Jacqueline Hoogendam started her professional career as a lawyer in the private sector. In 1994 she switched to the Dutch government, the Ministry of Justice, with special responsibility on crime prevention and business ethics. After developing a chronic disease herself, she was offered a position at the Ministry of Health, Welfare and Sport in 2007. At the Department of Long Term Care she became responsible for dementia care. In the past years she extended this position to dementia policy co-ordinator for the entire ministry on both a national and an international level. As a part of this job, Jacqueline represents the Dutch government in, among others, the Executive Board of the Joint Programme Neurodegenerative Disease Research (JPND), the World Dementia Council and the European Governmental Group of Experts on Dementia.



Jeremy Hughes works in health and social care and is former Chief Executive of the Alzheimer's Society in the UK, where he led the charity in its five-year strategy "The New Deal on Dementia 2017-22". He was awarded the CBE for services to older people in the Queen's Birthday Honours 2015.

Jeremy Hughes


Vice chair, World
Dementia Council



Dr Sebastian Köhler

Associate professor,
Department of
Psychiatry and
Neuropsychology
and a principal
investigator, School
for Mental Health
and Neuroscience and
the Alzheimer Center
Limburg, Maastricht
University Medical
Center+

Seb is an associate professor at Department of Psychiatry and Neuropsychology and a principal investigator at the School for Mental Health and Neuroscience and the Alzheimer Center Limburg at Maastricht University Medical Center+. He leads the research line Neuroepidemiology, which specializes in research into risk and protective factors for cognitive decline and dementia and its translation into public health. Seb's group developed the LIBRA prevention score and eHealth tools, which are used in several ongoing prevention studies. He is a member of the Management Board of The Maastricht Study, a deep-phenotyping cohort of 9,000 individuals, and co-PI of the 25-year follow-up Maastricht Ageing Study. He co-leads the FINGER-NL trial, a 2-year multidomain lifestyle intervention program to promote brain health in older adults, which is part of the World Wide FINGER network, starting recruitment in Summer 2021.



Lydia Lanman

Senior Global Access
Policy Leader,
Hoffmann-La Roche


Lydia Lanman is the Senior Global Access Policy Leader at Hoffmann-La Roche and is responsible for global health policy efforts in neuroscience, rare disease, immunology, ophthalmology and influenza. Her area of expertise is brain health and Alzheimer's disease. Lydia joined the pharmaceutical industry in Canada in 2007, where she led a variety of national policy, government relations and market access efforts at two pharmaceutical firms. Prior to joining pharma, Lydia worked in various senior advisory roles in Canada, providing strategic advice directly to Ministers and Deputy Ministers of Health, both federally and provincially, on the development of health care policy, health system design and intergovernmental relations. Lydia holds a Bachelor of Arts in Political Science and a Master of Arts in Political Science/Public Health, both from the University of Alberta. Her graduate work focused primarily on Canadian and international health care reform.



Professor Nicola Lautenschlager

Professor of
Psychiatry of Old
Age and Director of
the Academic Unit
for Psychiatry of Old
Age, University of
Melbourne

Nicola T Lautenschlager, MD, FRANZCP, is Professor of Psychiatry of Old Age and Director of the Academic Unit for Psychiatry of Old Age in the Department of Psychiatry at the University of Melbourne, Australia. She is a consultant old age psychiatrist at Royal Melbourne Hospital and conducts her clinical work in a memory clinic. She is Deputy Head of School and Research Director in the Melbourne Medical School, University of Melbourne. Nicola received her clinical and academic training in Germany and completed a postdoc in the Neurogenetics Section and the Center for Human Genetics at Boston University. She has a particular interest in dementia risk reduction with a current focus on translational and implementation research.



Dr Anja Leist

Associate Professor
in Public Health and
Ageing, University of
Luxembourg


Anja Leist is Associate Professor in Public Health and Ageing at the University of Luxembourg. Her research focuses on cognitive ageing and dementia, technology and ageing, and health inequalities from a social epidemiological and life course perspective. Anja is PI on several grants, among them a grant from the European Research Council, to pursue innovative research on cognitive ageing and dementia from a prevention and risk reduction perspective, with a focus on lifestyle behaviours and inequalities related to education and gender. Anja is elected Fellow of the Gerontological Society of America, and cofounder and advisor to the World Young Leaders in Dementia (WYLD) network that is now spanning 30 countries and 250+ professionals in the fields of dementia research, care, and innovation.



Professor Gill Livingston

Professor of Psychiatry
of Older People,
University College
London

Gill Livingston is Professor of Psychiatry of Older People, head of mental health care of older people's research department and deputy director of the Division of Psychiatry, University College London. She is also a consultant psychiatrist working in the memory clinic, Camden & Islington NHS Foundation Trust in the UK. Her research focuses on intervention to help people with dementia and their families. She leads the Lancet Standing Commission on Dementia Prevention, Intervention and Care. They contained the life course analysis of potentially modifiable risks in dementia and include with specific recommendations about what to do. This has impacted on policy as well as driven research and increased awareness. She has devised and tested successful interventions to help people and families with dementia. She is a UK National Institute of Health Research Senior Investigator.



Dr Natalie Marchant

Senior Research Fellow, University College London


Dr Natalie Marchant is a Senior Research Fellow based in the Division of Psychiatry at University College London. She received a BA from Williams College USA, PhD in Psychology at Sussex University UK, and did post-doctoral research in neuroimaging and cognitive neuroscience at the University of California, Berkeley USA. Her primary research interest is in understanding how lifestyle and psychological factors may increase risk or resilience to neurodegeneration, cognitive impairment and dementia. She is currently an investigator in several UK- and internationally-funded trials examining behavioural interventions to reduce dementia risk. This includes leading a multi-national clinical trial of a psychological intervention in at-risk older adults.



Maree McCabe

Chief Executive Officer, Dementia Australia

A recognised leader in the health and aged care sector Maree brings extensive experience across the health, mental health and aged care sectors to her current role. Her career accomplishments include leading the successful unification of Alzheimer’s Australia and rebranding to Dementia Australia, the development of technology at Alzheimer’s Australia Vic, Executive roles in aged care and mental health. Maree is a member of a number of commonwealth and international health and aged care sector committees and Boards. Maree is a member of the Alzheimer’s Disease International Asia Pacific Regional Committee and Chair of the Alzheimer’s Disease International Nominations Committee.



Mitchell McMaster

Research Coordinator,
Surgical, Treatment
and Rehabilitation
Service (STARS), Royal
Brisbane Hospital


Mitchell McMaster is an early career researcher with a focus on dementia risk reduction/prevention and improving the lived experience of people with dementia. He is currently working as Research Coordinator at the Surgical, Treatment and Rehabilitation Service (STARS), Royal Brisbane Hospital/University of Queensland (UQ). Previously, Mitchell worked as a Trial Manager on primary and secondary dementia risk reduction interventions at the Centre for Research on Ageing, Health and Wellbeing (CRAHW) and the Centre for Research Excellence in Cognitive Health, at the Australian National University (ANU). Mitchell's published research in the dementia space includes: systematic reviews, randomised controlled trials, pilot/feasibility studies, epidemiological and methods papers. Mitchell's PhD study Body, Brain Life of Cognitive Decline (BBL-CD) was a multidomain dementia risk reduction intervention for people with SCD/MCI. It was funded by Dementia Australia Research Foundation/ANU and received research awards from Neuroscience Research Australia, The Royal Commonwealth Society and Australian National Science Week.



Dr Susan Mitchell

Head of Policy,
Alzheimer's Research
UK

Dr Susan Mitchell is Head of Policy, as part of the policy and public affairs team at the UK's leading dementia research charity, with responsibility for developing evidence-based policy to support progress in the dementia research field. Susan has led on work around dementia risk reduction and Brain Health, leading a successful pilot in collaboration with Public Health England to expand dementia risk reduction messaging within the NHS Health Check and leading the publication of a recent report to reframe risk reduction as the concept of brain health. She has experience of management in the NHS and health policy in several clinical areas.



Dr Cath Mummery

Consultant neurologist and leads the Cognitive Disorders Service, National Hospital for Neurology and Neurosurgery


Cath Mummery is a consultant neurologist, and leads the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery. She is head of clinical trials at the Dementia Research Centre, University College London and has been chief investigator on over 20 early phase drug trials of potential disease modifying agents, including the ground-breaking platform trial DIAN-TU in presymptomatic individuals at risk of familial AD, and a first-in-human antisense oligonucleotide study, targeting MAPT to reduce tau in AD. She has a particular interest in early phase studies and genetic therapies, and in the psychological impact of trial participation. She sits on a number of advisory boards for potential disease modifying agents and for dementia service development. She is deputy director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to the conduct of early phase trials in neurodegeneration.



Dr Graciela Muniz-Terrera

Senior Lecturer, Biostatistics and Epidemiology, Centre for Dementia Prevention

Dr. Muniz Terrera is a Senior Lecturer in Biostatistics and Epidemiology at the Centre for Dementia Prevention. She is affiliated to the EPAD (European Prevention of Alzheimer's Dementia) and the PREVENT studies and also works with an extensive network of international collaborators, many of them based in low and middle income countries. Before working in Edinburgh, she was a Lecturer at UCL and also worked for several years in Cambridge at the MRC Biostatistics Unit, where she also did her PhD. Her research has been supported by the Medical Research Council, the Alzheimer's Society, National Institute of Health (US) and various other funding organisations. Graciela has extensive experience developing and applying longitudinal methods to gain a better understanding of ageing, brain health and dementia. She is particularly interested in the study of modifiable risk factors for cognitive and physical decline and brain health.



Dr Ryoji Noritake

CEO and Board
Member, Health and
Global Policy Institute
(HGPI)


Ryoji Noritake is the CEO, Board Member of Health and Global Policy Institute (HGPI), a Tokyo-based independent and non-profit health policy think tank established in 2004. He was a member of Tokyo Metropolitan Government's Policy Discussion Roundtable for Super Ageing Society (2018). He is a graduate of Keio University's Faculty of Policy Management, holds a MSc in Medical Anthropology from the University of Amsterdam, the Netherlands. He is currently a Visiting Scholar at the National Graduate Institute for Policy Studies, a member of Salzburg Global Seminar's Advisory Council and serves as a member for various ageing related committees in Japan.



Dr Ruth Peters

Associate Professor,
University of New
South Wales

Dr Ruth Peters is an Associate Professor in the Department of Psychology at the University of New South Wales and a Senior Research Scientist at Neuroscience Research Australia. Her research interests centre around vascular risk factors for dementia and risk reduction, particularly blood pressure, antihypertensive use and cognition. Of note, she was the cognitive lead for the award winning Hypertension in the Very Elderly Trial which looked at blood pressure lowering, cardiovascular and cognitive outcomes in the over 80s. Both her evidence synthesis and original research have been cited by guidelines in dementia and vascular risk reduction.



Professor Martin Prince

Professor of
Epidemiological
Psychiatry, King's
College London


Martin Prince is Professor of Epidemiological Psychiatry at King's College London. He trained in Psychiatry at the Maudsley Hospital and in Epidemiology at the London School of Hygiene and Tropical Medicine. His work is oriented to the salience of mental and neurological disorders to health and social policy in low and middle income countries (LMIC), with a focus on ageing, dementia and other chronic disease. He has coordinated, since 1998 the 10/66 Dementia Research Group, a network of researchers, mainly from LMIC working together to promote more good research into dementia in those regions. The group has published 140 papers covering dementia prevalence, incidence, aetiology and impact and contributed to knowledge of public health aspects of ageing and chronic disease in LMIC. He co-authored the Dementia UK report that informed the UK Government's National Dementia Strategy.



Dr Kylie Radford

Clinical
neuropsychologist
and Senior Research
Scientist, Neuroscience
Research Australia
(NeuRA)

Dr Kylie Radford is a clinical neuropsychologist and Senior Research Scientist at Neuroscience Research Australia (NeuRA). She is also a Conjoint Senior Lecturer with the School of Psychology at the University of New South Wales, Sydney. Her diverse clinical research experience has involved studying early onset dementia, alcohol dependence and cognitive rehabilitation for acquired brain injuries, mild cognitive impairment and epilepsy. Over the past 10 years, her research has focused on the epidemiology, neuropsychology and sociocultural experience of ageing and dementia with older Aboriginal and Torres Strait Islander peoples. Working in close collaboration with Aboriginal communities, this work has highlighted the high prevalence and incidence of dementia in this population, and potentially modifiable risk factors across the life course. Current research aims to promote ageing well, identify dementia prevention strategies, and translate findings into culturally sensitive dementia education and care.



Professor Craig Ritchie

Professor of Psychiatry of Ageing, University of Edinburgh


Craig Ritchie is the Professor of Psychiatry of Ageing at the University of Edinburgh. His research interest is in the association between mid life risks of neurodegenerative disease and their phenotypic expression. This work will help uncover early disease mechanisms and therein potential for both pharmacological and non-pharmacological interventions. He is Chief Investigator on both the PREVENT Dementia and European Prevention of Alzheimer's Dementia Programmes. Most recently he established with partners in Alzheimer Scotland and Scottish Government 'Brain Health Scotland' which seeks to translate the emerging individual and population level research into a newly established national network of Brain Health Clinics and Public Health Policy respectively. He is also the Chairperson of the Scottish Dementia Research Consortium.



Professor Martin Rossor

NIHR National Director for Dementia Research, UCL Queen Square Institute of Neurology

Martin Rossor is the NIHR National Director for Dementia Research, Professor Emeritus, and Principal Research Associate at the UCL Queen Square Institute of Neurology. Following his training in clinical neurology at the National Hospital, Queen Square, Martin undertook primary research on the neurochemistry of degenerative dementia at the MRC Neurochemical Pharmacology Unit, Cambridge, before being appointed as Consultant Neurologist at St. Mary's Hospital London and the National Hospital in 1986. Martin was appointed as the Chairman of the Division of Neurology in 2002, after becoming Professor of Clinical Neurology. He established a specialist cognitive disorders clinic, which acts as a tertiary referral service for young onset and rare dementias. Martin's clinical research interests are in the degenerative dementias, particularly familial disease, and more recently in general cognitive impairment in systemic disease and multimorbidity.



Dr Cecilia Samieri

Permanent Researcher,
INSERM (French
National Institute for
Health)

After a doctorate in veterinary medicine, Cécilia Samieri obtained a doctorate in epidemiology from the University of Bordeaux (France) in 2009, and then trained as a postdoctoral fellow at the Channing Division of Network Medicine, Harvard Medical School (Boston, USA). Back in France, she joined INSERM (French National Institute for Health) as a permanent researcher in 2015, in the Bordeaux Population Health Research Center, INSERM U1219.


Cécilia Samieri's research focuses on the exposome of brain aging, with the main objective of understanding how environmental factors, including nutrition and cardiometabolic health, influence the etiology of age-related brain diseases, such as dementia and its leading cause, Alzheimer's disease. She has worked on several large cohorts on dementia and cognitive decline, studying with a holistic view the influence of lifestyle on brain health, from overall lifestyle patterns (eg, dietary patterns) to molecular markers of the exposome. Cécilia Samieri has led several projects on the environmental risk factors of Alzheimer's disease, and she is academic co-chair of the Alzheimer's Association's Professional Interest Area group on Nutrition and Metabolic Diseases.



Professor Suzana Shahar

Professor in Nutrition
and Dietetics, Centre
for Healthy Aging and
Wellness, Universiti
Kebangsaan Malaysia

Dr Suzana Shahar is a Professor in Nutrition and Dietetics from the Healthy Aging and Wellness Research Centre, Faculty of Health Sciences, Universiti Kebangsaan Malaysia. She is currently the Dean of the Faculty of Health Sciences, Universiti Kebangsaan Malaysia. She obtained her BSc (Hons) (Dietetics) from Universiti Kebangsaan Malaysia and then pursued her study to obtain MMed Sci (Human Nutrition) and PhD (Human Nutrition) from the University of Sheffield, UK. Her research interest is on nutrition and epidemiology of aging, nutrition and neuroscience and cancer. She has just completed a nationwide project on 'Neuroprotective Model for Healthy Longevity among Malaysian Elderly', funded by the Ministry of Education. She is currently leading a clinical trial (LRGS Ageless) to reverse cognitive frailty among Malaysian older adults funded by the Ministry of Higher Education, under the auspice of the World Wide Finger Trial.



Professor David Smith

Professor Emeritus
of Pharmacology,
University of Oxford


Professor Smith is Professor Emeritus of Pharmacology at the University of Oxford. He has spent his entire academic career in the University of Oxford, graduating from Christ Church in 1963. He was awarded the Gaddum prize medal of the British Pharmacological Society in 1979. He was founding Chief Editor of Neuroscience for 25 years from 1976. From 1984-2005 he was Chair and Head of Pharmacology at Oxford. He was Founding Director (1985) of the MRC Anatomical Neuropharmacology Unit. In 1988 he co-founded the Oxford Project to Investigate Memory and Aging (OPTIMA). He was Deputy-Head (Vice-Dean) of the Division of Medical Sciences at Oxford from 2000-2005. He has honorary doctorates from the Universities of Szeged and Lund and is a member of the Hungarian and Norwegian Academies of Science. In 2000 he was elected Fellow of the Academy of Medical Sciences, UK. In 2006 he was made the first Honorary Research Fellow of Alzheimer's Research UK, after serving as the first Chair of their Scientific Advisory Board.



Dr Heather Snyder

Vice president,
Medical & Scientific
Relations, Alzheimer's
Association

Heather M. Snyder, Ph.D., is vice president, Medical & Scientific Relations at the Alzheimer's Association®. In this role, she oversees Association initiatives that accelerate innovative Alzheimer's research and provide opportunities for the global dementia community to connect and collaborate. Dr. Snyder is responsible for the progress the Association has made in Alzheimer's and dementia research funding. To increase knowledge about prevention and risk reduction, Dr. Snyder serves on the executive team for the U.S. Study to Protect Brain Health Through Lifestyle Intervention to Reduce Risk (U.S. POINTER). She holds a Ph.D. in molecular biology from Loyola University Chicago Stritch School of Medicine and a bachelor's degree in biology and religious studies from the University of Virginia.



Professor Bloss Stephan

Professor in
Neuroepidemiology
and Global Ageing,
University of
Nottingham


Professor Stephan completed her training in psychology and mathematical statistics at Sydney University in Australia (1997-99; Honors Class I, Psychology, 2000). Her PhD was in the field of clinical neuropsychology, undertaken at the School of Psychology at Sydney University (2001-04). She completed her postdoctoral training in epidemiology and public health at Cambridge University, at the Institute of Public Health and Primary Care (2006-08). In 2008, she was awarded the EU Future Leaders in Ageing Research Fellowship, as the UK representative of this award (2008-11), and in 2011 became a senior research associate in risk prediction at Cambridge University. In 2012, she was appointed as a lecturer within the Ageing, Health and Society Research Group at the Institute of Health and Society, at Newcastle University. She was promoted to senior lecturer in August 2015. She moved to Nottingham University, in June 2019, to become a Professor in Neuroepidemiology and Global Ageing. She has published more than 150 peer-reviewed articles and has a funding portfolio (including PI and Co-I) of over £5M. Professor Stephan's research focuses on issues related to risk prediction and risk reduction of neurodegenerative diseases. This includes programs of work in high-income as well as low and middle income countries.



Professor Katsuya Urakami

Professor of Neurology,
Tottori University
School of Medicine

Neurologist, Professor, Tottori University School of Medicine. Specialized fields: Dementia prevention, biomarker for early diagnosis, epidemiology. Affiliated academic society / certification / qualification: Japanese Society of Dementia Prevention (Chairman / Specialist) Japanese Psychogeriatric Society (Director), The Japan Gerontological Society (Director), Japanese Society of Neurology (specialist / instructor, The Japan Geriatrics Society (Representative / Instructor), Japanese Society for Dementia Research (Representative / Specialist).



Professor James Vickers

Director of the Wicking Dementia Research and Education Centre and Dean, Tasmanian School of Medicine

Professor James Vickers is the Director of the Wicking Dementia Research and Education Centre and Dean of the Tasmanian School of Medicine. His research work has mainly focussed on neurodegenerative conditions, particularly Alzheimer's disease, as well as neural injury, the neuronal cytoskeleton, dementia risk reduction and health services for dementia. Professor Vickers has led developments in dementia education, including free online courses that have reached hundreds of thousands of participants. Professor Vickers is a Past-President of the Australasian Neuroscience Society, is a member of the National Health and Medical Research Council Principal Health Innovation Advisory Committee, and a Board Member of Dementia Australia Research Foundation and Glenview Community Services.



Dr Lindsay Wallace

Canadian Banting Postdoctoral Fellow, University of Cambridge

Lindsay is a Canadian Banting Postdoctoral Fellow at the University of Cambridge in Public Health. She is from Halifax, Nova Scotia in Canada and has earned an MSc from McGill University (Neuroscience), and a PhD from Dalhousie University (Interdisciplinary Health Studies). She blends insights from epidemiology, public health, and neuroscience to better understand how dementia arises and how public health approaches may be able to address prevention. The majority of her work to date has used data from large epidemiologic clinico-pathologic studies to answer questions about how ageing and frailty are related to the pathology and clinical expression of dementia. As a postdoc under the supervision of Prof. Carol Brayne, she is now investigating scalable public health approaches to reduce population dementia risk.

The World Dementia Council (WDC) is an international charity. It consists of senior experts and leaders drawn from research, academia, industry, governments and NGOs in both high-income and low- and middle-income countries, including two leaders with a personal dementia diagnosis. The WDC has an executive team based in London, UK.

worlddementiacouncil.org

© 2020 World Dementia Council
UK charity registration number: 1170743

Cover image editorial credit: Shutterstock.com

